Efficacy and Safety of Intensive Blood Pressure Therapy Using Restricted Mean Survival Time—Insights from the SPRINT Trial

Ashok Krishnaswami; Eric D. Peterson; Dae Hyun Kim; Parag Goyal; Michael W. Rich

doi:10.1016/j.amjmed.2019.12.050

Efficacy and Safety of Intensive Blood Pressure Therapy Using Restricted Mean Survival Time—Insights from the SPRINT Trial

Ashok Krishnaswami, Eric D. Peterson, Dae Hyun Kim, Parag Goyal, Michael W. Rich

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	e369-e370
Journal	American Journal of Medicine
Volume	133
Issue number	7
DOIs	https://doi.org/10.1016/j.amjmed.2019.12.050
State	Published - Jul 2020
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.amjmed.2019.12.050

Cite this

@article{de3479939b794403b8902e73d9208570,

title = "Efficacy and Safety of Intensive Blood Pressure Therapy Using Restricted Mean Survival Time—Insights from the SPRINT Trial",

author = "Ashok Krishnaswami and Peterson, {Eric D.} and Kim, {Dae Hyun} and Parag Goyal and Rich, {Michael W.}",

note = "Funding Information: Funding: DHK supported by NIA grant R21AG060227. Conflicts of Interest: EP receives research funding from AstraZeneca, Janssen, Amgen, and Sanofi. AK, DHK, PG, MWR report none. Funding Information: Funding: DHK supported by NIA grant R21AG060227 . ",

year = "2020",

month = jul,

doi = "10.1016/j.amjmed.2019.12.050",

language = "English (US)",

volume = "133",

pages = "e369--e370",

journal = "American Journal of Medicine",

issn = "0002-9343",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Efficacy and Safety of Intensive Blood Pressure Therapy Using Restricted Mean Survival Time—Insights from the SPRINT Trial

AU - Krishnaswami, Ashok

AU - Peterson, Eric D.

AU - Kim, Dae Hyun

AU - Goyal, Parag

AU - Rich, Michael W.

N1 - Funding Information: Funding: DHK supported by NIA grant R21AG060227. Conflicts of Interest: EP receives research funding from AstraZeneca, Janssen, Amgen, and Sanofi. AK, DHK, PG, MWR report none. Funding Information: Funding: DHK supported by NIA grant R21AG060227 .

PY - 2020/7

Y1 - 2020/7

UR - http://www.scopus.com/inward/record.url?scp=85081909687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081909687&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2019.12.050

DO - 10.1016/j.amjmed.2019.12.050

M3 - Article

C2 - 32061731

AN - SCOPUS:85081909687

SN - 0002-9343

VL - 133

SP - e369-e370

JO - American Journal of Medicine

JF - American Journal of Medicine

IS - 7

ER -

Efficacy and Safety of Intensive Blood Pressure Therapy Using Restricted Mean Survival Time—Insights from the SPRINT Trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this